The old maxim that tech transfer is a “contact sport” has never been more apt than in today’s environment. But the meaning of “contact” has expanded, from the individual to the institutional, as an increasing web of partnerships among universities, corporations, government agencies, economic development groups, and investors has come to characterize a wide swath of research commercialization activity. The trend is a reflection of the increasing sophistication and business-like approach that TTOs are adopting to expand and thrive in a more connected and interdependent world.
And as any business executive will attest, partnerships can succeed wildly or fail miserably, depending on how they are structured, nurtured, and operated. To optimize the results of your partnering agreements takes diligent work before and after the deal is inked. That’s why our Distance Learning Division has scheduled a targeted 90-minute session — with the top tech transfer official from the National Institutes of Health and a TTO exec who’s a partnering veteran — to help ensure you make the most of these opportunities. This program will provide loads of practical guidance from two outstanding speakers:
Tech Transfer Partnerships: Establishing Effective Legal and Operational Structures for Long-Term Success
Here’s a unique opportunity to hear from the point person for tech transfer at one of the biggest government funding sources for university research. Mark Rohrbaugh, PhD, JD, Director of the National Institutes of Health’s Office of Technology Transfer, will provide insider knowledge and advice on:
- NIH’s strategy for determining patentability
- Examples of successful licensing and partnership structures
- Post-licensing monitoring and enforcement operations
- Procedures for managing license flexibility in regard to large vs. small companies and US vs. foreign firms
- Success stories of products stemming from clinical trials and partnerships
- Resources dedicated to assisting in technology development and commercialization
- Tips and success strategies for working effectively as an NIH CRADA partner
From the TTO front-lines and just returned from EuroBIO and AusBIO, Gary Breit, Executive Director of the University of Manitoba Technology Transfer Office, will bring an international perspective on deal structure, alliance management and new directions in technology development and commercialization collaborations.
- Popular transaction structures (including creative equity deals)
- A look at two decades-long alliances, and the lessons learned along the way
- A new paradigm for the “neural networks” that are being discussed in Europe and Asia — new collaborative models that promise to deliver solutions (rather than merely patents)
Your Expert Speakers:
Mark L. Rohrbaugh, PhD, JD, is Director of the U.S. National Institutes of Health Office of Technology Transfer. He previously served as the Director, Office of Technology Development, for the U.S. National Institute of Allergy and Infectious Diseases (NIAID), where he managed staff responsible for the negotiating technology transfer agreements with industry and academic institutions, including both intramural basic and clinical research and extramural cooperative networks. Prior to joining the NIH, Dr. Rohrbaugh conducted molecular and cell biology research in academic and industrial laboratories. He received his PhD in biochemistry from The Pennsylvania State University and a degree in law (J.D.) with honors from The George Washington University Law School.
Garold Briet, Executive Director of the University of Manitoba Technology Transfer Office, is a leader with extensive experience in technology-based organizations. His career began at Revlon, where he served as a Senior Marketing Manager and member of the Corporate Acquisitions Team. Mr. Breit has founded, financed and served as the president of biopharmaceutical companies (Antibodies, Inc. and RedStorm Scientific) and has launched successful intellectual asset programs at dramatically different academic institutions (Creighton University, the University of South Alabama, and the University of Texas). Today, Gary is the Executive Director of the Technology Transfer Office at the University of Manitoba, one of Canada’s most productive intellectual asset programs.
Richard U. Rodriguez, M.B.A. Since June 2008, Mr. Rodriguez has been the Director of the Division of Technology Development and Transfer (DTDT) in the Office of Technology Transfer (OTT) at the National Institutes of Health (NIH). DTDT is responsible for evaluating, patenting, marketing and licensing technologies developed at the NIH and the Food and Drug Administration (FDA). Prior to this, Mr. Rodriguez was the Chief of the Cancer Branch, which is one of three transactional branches within DTDT. In his capacity as Director, DTDT, he executes all license agreements on behalf of NIH and FDA, and he provides technical, operational and administrative expertise as well as guidance on intellectual property matters to leadership and staff across these organizations. These activities also include interactions with outside patent counsel, extramural institutions and commercial entities. Mr. Rodriguez has worked in the technology transfer field for fifteen years and has been with OTT for over eleven years. Prior to joining OTT, Mr. Rodriguez worked in the Office of Legal Affairs at UT Southwestern Medical Center in Dallas, Texas. Mr. Rodriguez has over nine years of scientific research experience in the areas of cancer biology and physiology. He earned his B.S. in Biology at Vanderbilt University and holds an M.B.A. from the University of Houston. Mr. Rodriguez is also a registered Patent Agent.